04/04/2011
Dear Shareholder,
As promised at the AGM on the 28th January, this is the first ‘RGT Bulletin’ e-mail alert to advise you of general progress with the company since its demerger. Whilst it is the intention to issue such a bulletin at approximately quarterly intervals the actual frequency and timing may vary slightly depending on what there is to report.
Since RGT came into being on the 18th February we have made steady progress:
- A press release was issued by both Metagenics (in the USA) and RGT (Internationally) on 18/2/11 announcing that Metagenics were changing to a daily dosing regimen (See: www.regentherapeutics.co.uk). This – together with a price reduction and a revamped marketing campaign is expected to increase market penetration. Metagenics have prepared a report on the daily dosing tolerance study that they performed to support this change. This is now being shared with current licensees who launched with the old dosing regimen to assist them in making the change.
- A press release was issued by RGT on the 11/3/11 announcing that MBM Partners had been appointed regional distributors for the MENWA region (See: www.regentherapeutics.co.uk). MBM have already identified several interested parties with a presence across most of the region. Preliminary negotiations are now ongoing with a view to appointing sub-distributors.
- Both of the above releases generated significant wire-media coverage and have led to several enquiries from potential licensees which are now being followed up.
- The new Filtration Unit is scheduled to be delivered to Sterling our contract manufacturer mid-April where it will undergo final testing. A new production run will then be performed as soon as possible.
- Framingham, Argentina has advised us that they have submitted an import/regulatory application for a locally developed Colostrinin formulation under the terms of our Material Transfer Agreement. Feedback from the authorities is now awaited. If positive a full Licensing and Distribution Agreement will be negotiated and put in place.
- LG Life Sciences in South Korea have also advised us that import and regulatory documents have been submitted to the authorities there. Feedback is awaited.
- Several shareholders have requested a meeting (perhaps during May/June) to ‘become better acquainted with the management and the company’s business’. Given the cost and resources associated with holding such a meeting I would be grateful if shareholders could let me know if this would be of interest to them and whether they would want to attend (London). Please reply to: head.office@regentherapeutics.com. When replying please indicate the number of shares you hold and the name/nominee account under which they are held to enable me to check this against the Shareholder Register.
Finally – as I know shareholders talk to each other, if any of you become aware of major questions and uncertainties about the business among a significant number of shareholders, please feel free to communicate these to me via the above e-mail address. If possible and these issues are significant, I will then attempt to clarify/address them by sending out a Shareholder Bulletin such as this one. If you know of any shareholders that are not signed up to receive our e-mail alerts please recommend that they sign up via the website.
Regards, Tim Shilton, CEO